Skip to main content

Novartis vs Roche: Founders, CEOs and History

Novartis was founded in 1996 by Daniel Vasella, Alex Krauer and is led by Vasant Narasimhan. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.

Company facts

Novartis

Founded
1996
Headquarters
Basel, Switzerland
Current CEO
Vasant Narasimhan
Employees
75,267

Roche

Founded
1896
Headquarters
Basel, Switzerland
Current CEO
Thomas Schinecker
Employees
112,774

Founders

Novartis

  • Daniel Vasella

    Novartis was formed in December 1996 when Ciba-Geigy and Sandoz merged in a deal valued at roughly $27 billion, then among the largest corporate mergers on record.

  • Alex Krauer

    Alex Krauer was the first chairman of Novartis, serving from the company's formation through the roughly $27 billion merger of Ciba-Geigy and Sandoz in 1996 until 1999, when the board named CEO Daniel Vasella to replace him as chairman.

Novartis founders in full

Roche

  • Fritz Hoffmann-La Roche

    Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.

Roche founders in full

CEOs and their tenures

Novartis

  1. Joseph Jimenez2010–2018

    Chief Executive Officer

    Serving as CEO from 2010 to 2018, he fundamentally transformed the massive Swiss conglomerate, heavily trimming its bloated divisions to create a highly focused, pure-play innovative medicines company.

    Source
  2. Vas Narasimhan2018–present

    Chief Executive Officer

    Narasimhan, a physician who previously led global drug development, became CEO on February 1, 2018.

    Source
  3. Giovanni Caforio2025–present

    Chair of the Board

    As a highly influential Board Member (and former BMS CEO), he brings unmatched global oncology expertise to Novartis's executive committee.

    Source
  4. Mukul Mehta2026–present

    Chief Financial Officer

    As CFO, he aggressively deploys massive amounts of capital toward high-risk, high-reward biotech acquisitions, ensuring Novartis maintains a dominant pipeline of blockbuster drugs.

    Source
Novartis CEO history in full

Roche

  1. Fritz Gerber1978–1998

    Chairman and Chief Executive Officer

    He bought a majority of Genentech in 1990 and Boehringer Mannheim in 1997. Franz Humer succeeded him as chief executive in 1998.

    Source
  2. Severin Schwan2008–2023

    Chief Executive Officer

    Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.

    Source
  3. Thomas Schinecker2023–present

    Chief Executive Officer

    Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.

    Source
Roche CEO history in full

Timeline: Novartis and Roche side by side

  1. 1859Novartis

    Founding of Ciba

    Silk dyer Alexander Clavel began producing the synthetic dye fuchsine in Basel, Switzerland, marking the origin of Ciba, part of the Ciba-Geigy half of the Novartis merger.

  2. 1886Novartis

    Founding of Sandoz

    Alfred Kern and Edouard Sandoz founded the chemical company Kern & Sandoz in Basel, establishing the second half of the corporate lineage that would eventually merge to form Novartis.

  3. 1896Roche

    F. Hoffmann-La Roche Founded in Basel

    Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.

  4. 1898Roche

    Commercial Breakthrough with Sirolin

    Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.

  5. 1934Roche

    First Industrial Synthesis of Vitamin C

    Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.

  6. 1963Roche

    Launch of Valium (Diazepam)

    Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.

  7. 1968Roche

    Establishment of Roche Diagnostics

    Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.

  8. 1990Roche

    Majority Stake in Genentech

    Roche bought a majority stake in Genentech in 1990.

  9. 1996Novartis

    Merger of Ciba-Geigy and Sandoz

    Ciba-Geigy and Sandoz completed their merger in December 1996, a deal valued at roughly $27 billion, creating Novartis AG.

  10. 1997Roche

    Boehringer Mannheim Acquired

    Roche bought Corange, the parent of Boehringer Mannheim, in 1997 for about $11 billion.

  11. 2006Novartis

    Acquisition of Chiron Corporation

    Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.

  12. 2008Roche

    Severin Schwan becomes CEO

    Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.

  13. 2009Roche

    Full Acquisition of Genentech for $46.8 Billion

    Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.

  14. 2010Novartis

    Acquisition of Alcon

    Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.

  15. 2015Novartis

    DOJ Settlement

    Novartis paid $390 million to resolve US allegations that it gave kickbacks to specialty pharmacies to promote Exjade and Myfortic.

  16. 2018Novartis

    Vas Narasimhan Appointed CEO

    Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.

  17. 2018Roche

    Foundation Medicine & Flatiron Health Acquisitions

    Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.

  18. 2023Novartis

    Acquisition of Chinook Therapeutics

    Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.

  19. 2023Novartis

    Spin-off of Sandoz

    On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.

  20. 2023Roche

    Acquired Telavant

    F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.

  21. 2024Novartis

    Acquisition of MorphoSys

    Novartis acquired German biotech MorphoSys for about EUR 2.7 billion ($2.9 billion), adding the investigational myelofibrosis drug pelabresib.

  22. 2025Novartis

    FY2025 Financial Results

    Novartis reported FY2025 net sales of $54.5 billion, up 8%, with a core operating margin above 40% and free cash flow of $17.6 billion.

  23. 2025Novartis

    Entresto Generic Entry

    US generic versions of Entresto, Novartis's largest product, launched in 2025, starting the steepest patent cliff in the company's post-Sandoz history.

  24. 2025Roche

    Group Sales Reach CHF 61.5 Billion

    Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.

  25. 2026Novartis

    Avidity Biosciences Acquisition Closes

    On February 27, 2026, Novartis completed its roughly $12 billion acquisition of Avidity Biosciences, adding antibody-oligonucleotide conjugates for DM1, Duchenne and FSHD.

  26. 2026Novartis

    HARBOR Phase 3 Miss

    In September 2026, del-desiran missed the primary endpoint of the 159-patient Phase 3 HARBOR trial in myotonic dystrophy type 1, and NVS shares fell about 12.5% in pre-market trading.

Acquisitions

Novartis

  • Avidity Biosciences2026$12B
  • MorphoSys AG2024$2.9B
  • Chinook Therapeutics2023$3.5B
  • The Medicines Company2020$9.7B
  • Advanced Accelerator Applications2018$3.9B
  • Chiron Corporation2006$5.1B
All Novartis acquisitions

Roche

  • PathAI2026$1.1B
  • 89bio2025$3.5B
  • Telavant2023$7.1B
  • Carmot Therapeutics2023$2.7B
  • Foundation Medicine2018$2.4B
  • ForSight VISION42017Undisclosed
All Roche acquisitions

Questions about Novartis vs Roche

Who is the CEO of Novartis AG and F. Hoffmann-La Roche AG?

Novartis AG is led by Vasant Narasimhan and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Novartis AG founded vs F. Hoffmann-La Roche AG?

F. Hoffmann-La Roche AG was founded in 1896 — 100 years before Novartis AG, which was founded in 1996. F. Hoffmann-La Roche AG's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Novartis AG.

How many employees does Novartis AG have compared to F. Hoffmann-La Roche AG?

Novartis AG employs approximately 75,267 people, while F. Hoffmann-La Roche AG employs approximately 112,774. F. Hoffmann-La Roche AG has the larger workforce at 112,774 employees, compared to Novartis AG's 75,267. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Novartis AG and F. Hoffmann-La Roche AG headquartered?

Both Novartis AG and F. Hoffmann-La Roche AG are headquartered in Switzerland. Their local rules and tax obligations may still differ.

Who founded Novartis AG and F. Hoffmann-La Roche AG?

Novartis AG was founded by Daniel Vasella, Alex Krauer. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.

Which company has a longer operating history — Novartis AG or F. Hoffmann-La Roche AG?

F. Hoffmann-La Roche AG has been operating for approximately 130 years, making it the more established of the two companies. Novartis AG has been in operation for around 30 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Novartis vs Roche overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.